Clinical use of sirolimus-eluting stents

Cardiovascular Drug Reviews

Volumn 25, Issue 4, 2007, Pages 316-332

  Kirtane, Ajay J ^a   Leon, Martin B ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Coronary stents; PCI; Percutaneous coronary intervention; Rapamycin; Sirolimus; Sirolimus stents

Indexed keywords

RAPAMYCIN;

ANEURYSM; ANGIOCARDIOGRAPHY; ARTERY INTIMA PROLIFERATION; BLOOD VESSEL WALL; CLINICAL TRIAL; COST OF ILLNESS; DIABETES MELLITUS; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MECHANISM; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; HUMAN; IN-STENT RESTENOSIS; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RESTENOSIS; REVIEW; THROMBOSIS; TREATMENT OUTCOME; VASOMOTOR DISORDER;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG-ELUTING STENTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SIROLIMUS; TECHNOLOGY, PHARMACEUTICAL; TREATMENT OUTCOME;

EID: 36949011595     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2007.00024.x     Document Type: Review

References (84)

1. Beohar N, Davidson CJ, Kip KE, Goodreau L, Vlachos HA, Meyers SN, Benzuly KH, Flaherty JD, Ricciardi MJ, Bennett CL, et al 2007) Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 297 : 1992 2000.
2. Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL (2006) Bare metal stent restenosis is not a benign clinical entity. Am Heart J 151 : 1260 1264.
3. Colombo A, Hall P, Nakamura S, Almagor Y, Maiello L, Martini G, Gaglione A, Goldberg SL, Tobis JM (1995) Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 91 : 1676 1688.
4. Colombo A, Moses JW, Morice MC, Ludwig J, Holmes DR, Jr., Spanos V, Louvard Y, Desmedt B, Di Mario C, Leon MB (2004) Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation 109 : 1244 1249.
5. Daemen J, Garcia-Garcia HM, Kukreja N, Imani F, de Jaegere PP, Sianos G, van Domburg RT, Serruys PW (2007a) The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus. Eur Heart J 28 : 26 32.
6. Daemen J, Ong ATL, Stefanini GG, Tsuchida K, Spindler H, Sianos G, de Jaegere PPT, van Domburg RT, Serruys PW (2006) Three-year clinical follow-up of the unrestricted use of sirolimus-eluting stents as part of the rapamycin-eluting stent evaluated at rotterdam cardiology hospital (RESEARCH) registry. Am J Cardiol 98 : 895 901.
7. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Juni P, Sianos G, Hellige G, et al 2007b) Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 369 : 667 678.
8. Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, von Beckerath N, Ulm K, Wessely R, Dirschinger J, Schomig A (2005) Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 353 : 663 670.
9. Elezi S, Dibra A, Mehilli J, Pache J, Wessely R, Schomig A, Kastrati A (2006) Vessel size and outcome after coronary drug-eluting stent placement: Results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents. J Am Coll Cardiol 48 : 1304 1309.
10. Fajadet J, Morice M-C, Bode C, Barragan P, Serruys PW, Wijns W, Constantini CR, Guermonprez J-L, Eltchaninoff H, Blanchard D, et al 2005) Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: Three-year results of the RAVEL trial. Circulation 111 : 1040 1044.
11. Feres F, Munoz JS, Abizaid A, Albertal M, Mintz GS, Staico R, Centemero M, Mattos LA, Maldonado G, Tanajura LF, et al 2005) Comparison between sirolimus-eluting stents and intracoronary catheter-based beta radiation for the treatment of in-stent restenosis. Am J Cardiol 96 : 1656 1662.
12. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R (2007) Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialization. Circulation 115 : 2435 2441.
13. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K, Skorija K, Weber DK, Gold HK, Virmani R (2005) Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 112 : 270 278.
14. Gallo R, Padurean A, Jayaraman T, Marx S, Roque M, Adelman S, Chesebro J, Fallon J, Fuster V, Marks A, et al 1999) Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 99 : 2164 2170.
15. Ge L, Iakovou I, Cosgrave J, Chieffo A, Montorfano M, Michev I, Airoldi F, Carlino M, Melzi G, Sangiorgi GM, et al 2005) Immediate and mid-term outcomes of sirolimus-eluting stent implantation for chronic total occlusions. Eur Heart J 26 : 1056 1062.
16. Grines CL, Bonow RO, Casey DE, Jr., Gardner TJ, Lockhart PB, Moliterno DJ, O'Gara P, Whitlow P (2007) Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 115 : 813 818.
17. Holmes DR, Jr., Teirstein P, Satler L, Sketch M, O'Malley J, Popma JJ, Kuntz RE, Fitzgerald PJ, Wang H, Caramanica E, et al 2006) Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: The SISR randomized trial. JAMA 295 : 1264 1273.
18. Hong MK, Mintz GS, Lee CW, Park DW, Park KM, Lee BK, Kim YH, Song JM, Han KH, Kang DH, et al 2006) Late stent malapposition after drug-eluting stent implantation: An intravascular ultrasound analysis with long-term follow-up. Circulation 113 : 414 419.
19. Jeremias A, Sylvia B, Bridges J, Kirtane AJ, Bigelow B, Pinto DS, Ho KK, Cohen DJ, Garcia LA, Cutlip DE, et al 2004) Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 109 : 1930 1932.
20. Jimenez-Quevedo P, Sabate M, Angiolillo DJ, Alfonso F, Hernandez-Antolin R, Sanmartin M, Gomez-Hospital JA, Banuelos C, Escaned J, Moreno R, et al 2007) Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: Long-term results of the DIABETES trial. Eur Heart J 28 : 1946 52.
21. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R (2006) Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 48 : 193 202.
22. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, Menichelli M, Sabate M, Suttorp MJ, Baumgart D, et al 2007) Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 : 1030 1039.
23. Katritsis DG, Karvouni E, Ioannidis JP (2005) Meta-analysis comparing drug-eluting stents with bare metal stents. Am J Cardiol 95 : 640 643.
24. Kelbaek H, Helqvist S, Thuesen L, Klovgaard L, Jorgensen E, Saunamaki K, Krusell LR, Botker HE, Engstrom T, Jensen GV (2006) Sirolimus versus bare metal stent implantation in patients with total coronary occlusions: Subgroup analysis of the stenting coronary arteries in non-stress/benestent disease (SCANDSTENT) trial. Am Heart J 152 : 882 886.
25. Kerner A, Gruberg L, Kapeliovich M, Grenadier E (2003) Late stent thrombosis after implantation of a sirolimus-eluting stent. Catheter Cardiovasc Interv 60 : 505 508.
26. Kim Y-H, Park S-W, Lee S-W, Park D-W, Yun S-C, Lee CW, Hong M-K, Kim H-S, Ko J-K, Park J-H, et al 2006a) Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease. Circulation 114 : 2148 2153.
27. Kim YH, Lee BK, Park DW, Park KH, Choi BR, Lee CW, Hong MK, Kim JJ, Park SW, Park SJ (2006b) Comparison with conventional therapies of repeated sirolimus-eluting stent implantation for the treatment of drug-eluting coronary stent restenosis. Am J Cardiol 98 : 1451 1454.
28. Kim YH, Park SW, Lee CW, Hong MK, Gwon HC, Jang Y, Lee MM, Koo BK, Oh DJ, Seung KB, et al 2006c) Comparison of sirolimus-eluting stent, paclitaxel-eluting stent, and bare metal stent in the treatment of long coronary lesions. Catheter Cardiovasc Interv 67 : 181 187.
29. Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H, Mintz GS, Nagata S (2006) Incomplete neointimal coverage of sirolimus-eluting stents: Angioscopic findings. J Am Coll Cardiol 47 : 2108 2111.
30. Kuchulakanti PK, Chu WW, Torguson R, Clavijo L, Wolfram R, Mishra S, Xue Z, Gevorkian N, Suddath WO, Satler LF, et al 2006) Sirolimus-eluting stents versus paclitaxel-eluting stents in the treatment of coronary artery disease in patients with diabetes mellitus. Am J Cardiol 98 : 187 192.
31. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L and the SSG (2007) Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 : 1009 1019.
32. Lemos PA, Hoye A, Goedhart D, Arampatzis CA, Saia F, van der Giessen WJ, McFadden E, Sianos G, Smits PC, Hofma SH, et al 2004a) Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: An evaluation from the rapamycin-eluting stent evaluated at rotterdam cardiology hospital (RESEARCH) study. Circulation 109 : 1366 1370.
33. Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, Hoye A, Degertekin M, Tanabe K, Daemen J, Liu TKK, et al 2004b) Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": The rapamycin-eluting stent evaluated at rotterdam cardiology hospital (RESEARCH) registry. Circulation 109 : 190 195.
34. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, et al 1998) A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent anticoagulation restenosis study investigators. N Engl J Med 339 : 1665 1671.
35. Lotan C, Almagor Y, Kuiper K, Suttorp MJ, Wijns W (2006) Sirolimus-eluting stent in chronic total occlusion: The SICTO study. J Interv Cardiol 19 : 307 312.
36. Maekawa K, Kawamoto K, Fuke S, Yoshioka R, Saito H, Sato T, Hioka T (2006) Images in cardiovascular medicine. Severe endothelial dysfunction after sirolimus-eluting stent implantation. Circulation 113 : e850-851.
37. Marx SO, Jayaraman T, Go LO, Marks AR (1995) Rapamycin-fkbp inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 76 : 412 417.
38. Marx SO, Marks AR (2001) Bench to bedside: The development of rapamycin and its application to stent restenosis. Circulation 104 : 852 855.
39. Mauri L, Hsieh W-h, Massaro JM, Ho KKL, D'Agostino R, Cutlip DE (2007) Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 : 1020 1029.
40. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, Suddath WO, Weissman NJ, Torguson R, Kent KM, et al 2004) Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364 : 1519 1521.
41. Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, Pichard AD, Kent KM, Stone GW, Leon MB (1999) Angiographic patterns of in-stent restenosis: Classification and implications for long-term outcome. Circulation 100 : 1872 1878.
42. Meier B, Sousa E, Guagliumi G, Van den Branden F, Grenadier E, Windecker S, te Riele H, Voudris V, Eltchaninoff H, Lindvall B, et al 2006) Sirolimus-eluting coronary stents in small vessels. Am Heart J 151 : 1019 e1011 1017.
43. Menichelli M, Parma A, Pucci E, Fiorilli R, De Felice F, Nazzaro M, Giulivi A, Alborino D, Azzellino A, Violini R (2007) Randomized trial of Sirolimus-Eluting Stent versus bare-metal stent in Acute Myocardial Infarction (SESAMI). J Am Coll Cardiol 49 : 1924 1930.
44. Mercado N, Wijns W, Serruys PW, Sigwart U, Flather MD, Stables RH, O'Neill WW, Rodriguez A, Lemos PA, Hueb WA (2005) One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease: A meta-analysis of individual patient data from randomized clinical trials. J Thoracic Cardiovasc Surg 130 : 512 519.
45. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, et al 2002) A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 : 1773 1780.
46. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, et al 2003a) Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 : 1315 1323.
47. Moses JW, Nikolsky E, Mehran R, Cambier PA, Bachinsky WB, Leya F, Kuntz RE, Popma JJ, Schleckser P, Wang H (2006) Safety and efficacy of the 2.25-mm sirolimus-eluting bx velocity stent in the treatment of patients with de novo native coronary artery lesions: The SIRIUS 2.25 trial. Am J Cardiol 98 : 1455 1460.
48. Moussa I, Leon MB, Baim DS, O'Neill WW, Popma JJ, Buchbinder M, Midwall J, Simonton CA, Keim E, Wang P, et al 2004) Impact of sirolimus-eluting stents on outcome in diabetic patients: A SIRIUS (sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 109 : 2273 2278.
49. Moussa ID, Moses JW, Kuntz RE, Holmes DR, Popma JJ, Teirstein PS, Wong SC, Leon MB (2006) The fate of patients with clinical recurrence after sirolimus-eluting stent implantation (a two-year follow-up analysis from the SIRIUS trial). Am J Cardiol 97 : 1582 1584.
50. Nayak AK, Kawamura A, Nesto RW, Davis G, Jarbeau J, Pyne CT, Gossman DE, Piemonte TC, Riskalla N, Chauhan MS (2006) Myocardial infarction as a presentation of clinical in-stent restenosis. Circ J 70 : 1026 1029.
51. Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J, Davidson CJ, McKoy JM, Raisch DW, Whisenant BK, et al 2006) Hypersensitivity cases associated with drug-eluting coronary stents: A review of available cases from the research on adverse drug events and reports (RADAR) project. J Am Coll Cardiol 47 : 175 181.
52. Newell MC, Henry CR, Sigakis CJ, Unger BT, Larson DM, Chavez IJ, Burke MN, Traverse JH, Henry TD (2006) Comparison of safety and efficacy of sirolimus-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction. Am J Cardiol 97 : 1299 1302.
53. Nordmann AJ, Briel M, Bucher HC (2006) Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: A meta-analysis. Eur Heart J 27 : 2784 2814.
54. Pan M, de Lezo JS, Medina A, Romero M, Segura J, Pavlovic D, Delgado A, Ojeda S, Melian F, Herrador J, et al 2004) Rapamycin-eluting stents for the treatment of bifurcated coronary lesions: A randomized comparison of a simple versus complex strategy. Am Heart J 148 : 857 864.
55. Percoco G, Manari A, Guastaroba P, Campo G, Guiducci V, Aurier E, Sangiorgio P, Passerini F, Geraci G, Piovaccari G, et al 2006) Safety and long-term efficacy of sirolimus eluting stent in ST-elevation acute myocardial infarction: The REAL (Registro Regionale Angioplastiche Emilia-Romagna) registry. Cardiovasc Drugs Ther 20 : 63 68.
56. Pocock SJ, Henderson RA, Rickards AF, Hampton JR, King SB, Hamm CW, Puel J, Hueb W, Goy J-J, Rodriguez A (1995) Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery. The Lancet 346 : 1184 1189.
57. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR (1996) Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 98 : 2277 2283.
58. Sabate M, Jimenez-Quevedo P, Angiolillo DJ, Gomez-Hospital JA, Alfonso F, Hernandez-Antolin R, Goicolea J, Banuelos C, Escaned J, Moreno R, et al 2005) Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: The diabetes and sirolimus-eluting stent (diabetes) trial. Circulation 112 : 2175 2183.
59. Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM, Kuntz RE, Popma JJ (2004) The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 43 : 1110 1115.
60. Schampaert E, Moses JW, Schofer J, Schluter M, Gershlick AH, Cohen EA, Palisaitis DA, Breithardt G, Donohoe DJ, Wang H, et al 2006) Sirolimus-eluting stents at two years: A pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations and stent thromboses. Am J Cardiol 98 : 36 41.
61. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G (2003a) Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: Double-blind, randomised controlled trial (E-SIRIUS). Lancet 362 : 1093 1099.
62. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G (2003b) Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: Double-blind, randomised controlled trial (E-SIRIUS). Lancet 362 : 1093 1099.
63. Schuhlen H, Kastrati A, Mehilli J, Hausleiter J, Pache J, Dirschinger J, Schomig A (2004) Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement. Am Heart J 147 : 317 322.
64. Siqueira DA, Abizaid AA, Costa Jde R, Feres F, Mattos LA, Staico R, Abizaid AA, Tanajura LF, Chaves A, Centemero M, et al 2007) Late incomplete apposition after drug-eluting stent implantation: Incidence and potential for adverse clinical outcomes. Eur Heart J 28 : 1304 1309.
65. Sousa JE, Abizaid A, Guagliumi G, Lewis B, Mehran R, Lansky A, Cohen S, Fitzgerald PJ, Chaves A, Mattos LA (2005) Does the dose of sirolimus affect outcomes after drug-eluting stenting in diabetic patients? Final results of the double dose diabetes (3D) study. J Am Coll Cardiol 45 (Suppl 74A.
66. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM, Seixas AC, Staico R, Mattos LA, Sousa AG, et al 2001a) Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: A quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 103 : 192 195.
67. Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, Kozuma K, Van Langenhove G, Sousa AG, Falotico R, et al 2001b) Sustained suppression of neointimal proliferation by sirolimus-eluting stents: One-year angiographic and intravascular ultrasound follow-up. Circulation 104 : 2007 2011.
68. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW (2007) A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 : 989 997.
69. Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrie D, Slama MS, Merkely B, Erglis A, Margheri M, et al 2006) Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 355 : 1093 1104.
70. Stabile E, Escolar E, Weigold G, Weissman NJ, Satler LF, Pichard AD, Suddath WO, Kent KM, Waksman R (2004) Marked malapposition and aneurysm formation after sirolimus-eluting coronary stent implantation. Circulation 110 : e47-48.
71. Steigen TK, Maeng M, Wiseth R, Erglis A, Kumsars I, Narbute I, Gunnes P, Mannsverk J, Meyerdierks O, Rotevatn S, et al 2006) Randomized study on simple versus complex stenting of coronary artery bifurcation lesions: The nordic bifurcation study. Circulation 114 : 1955 1961.
72. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice M-C, Colombo A, Schampaert E, Grube E, Kirtane AJ, et al 2007) Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 : 998 1008.
73. Stone GW, Reifart NJ, Moussa I, Hoye A, Cox DA, Colombo A, Baim DS, Teirstein PS, Strauss BH, Selmon M, et al 2005) Percutaneous recanalization of chronically occluded coronary arteries: A consensus document: Part ii. Circulation 112 : 2530 2537.
74. Suttorp MJ, Laarman GJ, Rahel BM, Kelder JC, Bosschaert MAR, Kiemeneij F, ten Berg JM, Bal ET, Rensing BJ, Eefting FD, et al 2006) Primary Stenting of totally Occluded native coronary Arteries II (PRISON II): A randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. Circulation 114 : 921 928.
75. Suzuki T, Kopia G, Hayashi S-I, Bailey LR, Llanos G, Wilensky R, Klugherz BD, Papandreou G, Narayan P, Leon MB, et al 2001) Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 104 : 1188 1193.
76. Tanimoto S, Daemen J, Tsuchida K, Garcia-Garcia HM, de Jaegere P, van Domburg RT, Serruys PW (2006) Two-year clinical outcome after coronary stenting of small vessels using 2.25-mm sirolimus- and paclitaxel-eluting stents: Insight into the research and t-search registries. Catheter Cardiovasc Interv 69 : 94 103.
77. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators (1996) Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 335 : 217 225.
78. Urban P, Gershlick AH, Guagliumi G, Guyon P, Lotan C, Schofer J, Seth A, Sousa JE, Wijns W, Berge C, et al 2006) Safety of coronary sirolimus-eluting stents in daily clinical practice: One-year follow-up of the e-Cypher registry. Circulation 113 : 1434 1441.
79. Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Bruining N, Van den Branden F, Van Langenhove G (2006) Randomized double-blind comparison of SIROLIMUS-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: Six-month angiographic, intravascular ultrasound, and clinical follow-up of the rrisc trial. J Am Coll Cardiol 48 : 2423 2431.
80. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD (2004) Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious? Circulation 109 : 701 705.
81. Walpoth BH, Hess OM (2004) Late coronary thrombosis secondary to a sirolimus-eluting stent. Circulation 110 : e309 author reply e309.
82. Weisz G, Leon MB, Holmes DR, Jr., Kereiakes DJ, Clark MR, Cohen BM, Ellis SG, Coleman P, Hill C, Shi C, et al 2006) Two-year outcomes after sirolimus-eluting stent implantation: Results from the SIROLImus-eluting stent in de novo native coronary lesions (sirius) trial. J Am Coll Cardiol 47 : 1350 1355.
83. Win HK, Caldera AE, Maresh K, Lopez J, Rihal CS, Parikh MA, Granada JF, Marulkar S, Nassif D, Cohen DJ, et al 2007) Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 297 : 2001 2009.
84. Zavalloni D, Belli G, Rossi ML, Scatturin M, Morenghi E, Catalano G, Tosi G, Gasparini GL, Pagnotta P, Presbitero P (2006) Comparison between drug-eluting stents and beta-radiation for the treatment of diffuse in-stent restenosis: Clinical and angiographic outcomes. Am Heart J 152 : 908 e901 907.